CEO Nakayama says Daiichi Sankyo is helping Ranbaxy deal with the FDA's concerns

Japan's Daiichi Sankyo, which has controlling ownership of India's troubled Ranbaxy Laboratories, is helping Ranbaxy deal with all of its FDA regulatory issues. According to The Hindu Business Line, the assurances were made Thursday in talks between Daiichi Sankyo CEO George Nakayama and Commerce & Industry Minister Anand Sharma. Daiichi is starting with Ranbaxy's plant in Mohali, which the FDA banned in September from exporting to the U.S. citing a list of quality shortcomings. Daiichi acquired control of Ranbaxy in 2008, shortly before serious problems at two other Indian plants were uncovered by the FDA. Ranbaxy last May paid $500 million in fines and pleaded guilty to 7 charges tied to the issues. Those two plants have been banned from producing drugs for the U.S. since the problems were discovered. Daiichi has said it was misled as to how ugly Ranbaxy Laboratories' regulatory problems were before it bought the Indian generics maker and is in international mediation with former shareholders to recover some of its money. The company in the past has pledged to help Ranbaxy get its problems resolved with the FDA, but citations have continued to stack up. Story | More